Biology Reference
In-Depth Information
(Welsh et al., 2004). It has also been found to be effective inhibitor of growth of
xenografts models of human SCLC and adenocarcinoma of the lung (Jacoby et al.,
2010) and is currently being evaluated in advanced solid tumours and lymphoma
(NCT00522652). Liu (2012c) recently demonstrated that Sorafenib inhibited HIF-1α
and VEGF expression and also interfered with mTOR signalling in HCC cells and
HCC xenografts. A word of caution however is required since inhibition of HIFs
may have adverse effects in terms of promotion and enrichment of cancer stem cells
(Conley et al., 2012). A phase II trial of Sorafenib in ovarian epithelial cancer is
being carried out (NCT00522301).
Search WWH ::
Custom Search